Curated News
By: NewsRamp Editorial Staff
November 12, 2026
Novogenia to Lead DNA Analysis and Personalized Supplements in Abu Dhabi GLP-1 Study
TLDR
- Novogenia AG joins the 10XREVIV study in Abu Dhabi as exclusive technology partner, targeting the growing GLP-1 market and international expansion.
- Novogenia will perform DNA analyses, evaluate results, and develop personalized dietary supplements for 500 participants receiving GLP-1 therapy.
- Personalized nutrition from DNA analysis may improve nutritional status, body composition, and quality of life for GLP-1 therapy patients.
- A 2025 U.S. study found 22.4% of adults on GLP-1 therapy developed a nutrient deficiency within one year, highlighting the need for tailored support.
Impact - Why it Matters
This news matters because it signals a significant step toward integrating genetic personalization into mainstream obesity and diabetes care. As GLP-1 therapies like Ozempic and Wegovy become more widely used, concerns about nutrient deficiencies and muscle loss are growing. By tailoring nutritional supplements to individual DNA, Novogenia and its partners aim to enhance treatment outcomes and quality of life for patients. The study's findings could influence how healthcare providers support patients on GLP-1 therapy globally, potentially setting a new standard for personalized nutritional support. Moreover, Novogenia's expansion into the Middle East, including Halal certification, positions the company in a rapidly growing market, with the GLP-1 sector projected to exceed $185 billion by 2033. This initiative not only underscores the increasing role of genetics in preventive health but also highlights the economic potential of personalized healthcare solutions.
Summary
Novogenia AG, a Munich-based healthcare company specializing in human genetics and personalized products, has announced its exclusive role as technology and manufacturing partner in a planned clinical study under the 10XREVIV initiative in Abu Dhabi. The study, a collaboration with healthcare partners M42, 10X Health, and REVIV Global, aims to investigate the potential benefits of personalized dietary supplements for patients receiving GLP-1 therapy. Novogenia will conduct DNA analyses for participants, evaluate the results, and develop and manufacture tailored supplements based on individual genetic profiles. The study design initially calls for 500 participants in Abu Dhabi.
According to Dr. Daniel Wallerstorfer, CEO of Novogenia AG, "The 10XREVIV initiative is a key component of our international growth strategy." He added that the study aims to provide insights into the additional benefits of individually tailored nutritional support for people undergoing GLP-1 therapy. The initiative is part of Novogenia's broader push to expand its genetic analysis technologies and personalized health products in international markets, with preparations in the Middle East including product adaptation and Halal certification. The operational launch coincides with strong growth in the global GLP-1 therapy market, projected to rise from approximately $66 billion in 2025 to over $185 billion by 2033, according to market forecasts. A U.S. study published in 2025 involving more than 460,000 adults prescribed GLP-1 therapy found that 22.4% experienced a nutrient deficiency or related complication within one year, underscoring the importance of adequate nutrient intake during such treatments.
Novogenia's participation builds on its expertise in genetic analysis and personalized supplement manufacturing, strengthening its position as a technology and manufacturing partner in personalized healthcare. The company, headquartered in Munich, operates its own laboratory and serves as a partner to physicians, therapists, pharmacists, nutritionists, and fitness trainers. For more information, visit the company's website. The original release can be viewed on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Novogenia to Lead DNA Analysis and Personalized Supplements in Abu Dhabi GLP-1 Study
